Testing effectiveness (Phase 2)Ended earlyNCT00509496
What this trial is testing
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Who this might be right for
Skin CancerMelanoma
National Cancer Institute (NCI) 21